Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-14.86%
0%
-14.86%
6 Months
23.53%
0%
23.53%
1 Year
-7.35%
0%
-7.35%
2 Years
26.0%
0%
26.0%
3 Years
-10.0%
0%
-10.0%
4 Years
-25.88%
0%
-25.88%
5 Years
-21.25%
0%
-21.25%
Provexis Plc for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
14.17%
EBIT Growth (5y)
-0.20%
EBIT to Interest (avg)
-0.42
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.48
Sales to Capital Employed (avg)
0.55
Tax Ratio
1.44%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
14.49
EV to EBIT
-14.01
EV to EBITDA
-14.01
EV to Capital Employed
14.01
EV to Sales
11.68
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-47.48%
ROE (Latest)
-48.02%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
Bullish
Bollinger Bands
Sideways
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Annual Results Snapshot (Consolidated) - Mar'23
Mar'23
Mar'22
Change(%)
Net Sales
0.40
0.40
Operating Profit (PBDIT) excl Other Income
-0.40
-0.30
-33.33%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-0.40
-0.20
-100.00%
Operating Profit Margin (Excl OI)
-1,122.20%
-695.10%
-42.71%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2023 is 0.00% vs -20.00% in Mar 2022
Consolidated Net Profit
YoY Growth in year ended Mar 2023 is -100.00% vs 50.00% in Mar 2022
About Provexis Plc 
Provexis Plc
Pharmaceuticals & Biotechnology
Provexis plc is engaged in developing and licensing the Fruitflow heart-health functional food ingredient for the global functional food sector. Fruitflow is a tomato extract, which inhibits platelet aggregation that causes heart attack, stroke and venous thrombosis. The syrup and powder versions of Fruitflow are used in foods, beverages and supplements. The powder version is used in a range of products, including soft gels, capsules, tablets and stick packs. The Company also offers Fruitflow + Omega-3 dietary supplement product, which is a two-in-one supplement in an easy to take capsule supporting healthy blood flow and normal heart function. Fruitflow + Omega-3 dietary supplement product is available through its e-commerce Website www.fruitflowplus.com. The Company's subsidiaries include Provexis Nutrition Limited, Provexis Natural Products Limited and Provexis (IBD) Limited, which are engaged in providing functional food, medical food and dietary supplement technologies.
Company Coordinates 
Company Details
2 Blagrave Street , READING None : RG1 1AZ
Registrar Details






